“Create the Disease and Offer the Cure” appears to be the overriding mandate of allopathic medicine subsuming what I learned in medical school – “First Do No Harm.”
The most recent “disease” is asymptomatic atrial fibrillation. The article on a physician’s site reads “Asymptomatic Atrial Fibrillation: Should You Be Concerned?” And, of course, the conclusion is ‘Be Afraid, Be Very Afraid.’ That’s the essence of ‘marketing disease to the masses’ that I talked about in my Death by Modern Medicine book. Here’s a shocking excerpt:
“Famed Madison Avenue wunderkind, Albert Lasker, considered the “Father of Modern Advertising”, was also a central player in the “Reach for a Lucky instead of a sweet” campaign. Right after the successful Lucky Strike campaign was over, Lasker, having made the most money in the history of advertising, decided to retire and go into a new direction. He wanted to become a fundraiser for medical research. (more…)
Magnesium, the fourth most abundant mineral in the body, plays a crucial role in activating over 300 chemical responses. It is responsible for the proper formation of bones, maintaining normal muscle function, regulating body temperature, and proper absorption of calcium. Increasingly, medical science is coming to believe that magnesium and other minerals missing from today’s diet might prevent cognitive disorders such as ADD, ADHD and bipolar disorder, as well as help prevent Alzheimer’s and mental decline as we age. (more…)
Here’s an urgent warning for the hundreds of thousands of Americans who’ve taken the heart drug Multaq: The FDA says it may double the risk of death in some patients.
The alert comes out of a recent study cut short earlier this summer by the drug’s maker, Sanofi-Aventis — but the company didn’t bother to mention that whopper of a death risk at the time.
Nope, they only made a vague reference to a “significant increase” in heart problems and said in a press release that “patients currently taking Multaq should not stop their therapy and should consult their treating physician should they have any questions.” (more…)
Regulators with the Food and Drug Administration have warned that Multaq, a cardiac drug Sanofi, has been linked with fatal heart problems in a clinical trial the company recently ended.
In the study involving 3,000 patients, 32 who were taking Multaq died from cardiac-related problems compared with 14 who were taking a placebo. In all, nearly twice as many people suffered heart attacks, strokes and death than those in the placebo control group. (more…)
The new findings, presented Sunday at the American Society of Hematology (ASH) 2009 Meeting and published online in the New England Journal of Medicine, come hard on the heels of the RE-LY results, reported by heartwire, showing dabigatran to be superior to warfarin in preventing strokes and peripheral embolic events in patients with atrial fibrillation (AF) (more…)
I get more questions about atrial fibrillation than about almost any other cardiovascular subject. This mirrors what I see in my practice: my patients are more confused and fearful about atrial fibrillation than about any other condition.
To help you understand what atrial fibrillation is and the best ways to treat it, I’ve gathered many of the questions I’ve gathered over the years and provided answers for you. (more…)